Macrophage Pharma Seeks Funding To Take Novel Cancer Therapy Forward
CEO Says Money Would Fund Lead Asset’s Clinical Development
Executive Summary
Macrophage Pharma’s lead asset will advance to clinical trials next year, making a series B financing round necessary, the UK biotech’s CEO tells Scrip.
You may also be interested in...
GeNeuro To Tackle Long COVID By Targeting Ancestor Viral Gene Activation
Switzerland’s GeNeuro will study whether its monoclonal antibody temelimab can prevent long-COVID, after data for the first time linked activation of human endogenous retroviruses (HERVs) to the condition and its associated neurological symptoms.
Strong Diagnostics, Biosimilar Pain Expected In Roche Q1
Investors during Roche’s first-quarter update 21 April will be looking for guidance on the strong growth of biosimilar competition to its cancer mainstays and how this may be offset by the group’s pipeline.
Russia’s RDIF and Sberbank Launch $100m Start-Up Fund
Russian sovereign wealth fund and Sputnik V vaccine producer RDIF has teamed up with the country’s biggest bank to fund ‘home-grown’ tech and science-intensive start-ups.